being patient
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
EEGI final rocking. Close to 52wk high.
EEGI lots of accumulation today. .0015x.0016.
Zzzzz. Applications take a while so it might be a while before we get an update
Could this be the week? EEGI usually has news out by now.
No rebound until Monday. Same thing every week. I agree that it is a good time to buy though
Low volume drop. We won't see movement until next Monday
Next Monday. Like the past 4 weeks
EEGI turn n burn in progress
2milly EEGI BUY .0013 they want that wall gone!
EEGI round 2 = EOD run up to hod maybe .002
That is if the guys playing this get the amount of shares they want at .0012 & .0013
Either Someone really wants out or someone still wants cheap shares. Holding mine tight, to much manipulation and not enough dilution(all retail) going on for this not to run. IMO
.0012x.0013
Bid whackers
Wow. Mms must be scared to put up a spread like that. .0012x.0018 lol
Need to tighten that spread
EEGI .0017s up. Good start to the day!
This could be the start of a great week. EEGI
EEGI .0016s up
EEGI .0015s almost gone
EEGI could pop anytime. Keep it on your radar.
EEGI slow n steady release of news. Low volume drops. Steady accumulation. Like it!
No one wants to sell me .0002s
.0004s up
UNVC good to see it moving. Been in this a while as a lotto play. Looks like the lotto might pay off!
Go UNVC!!!!
EEGI consistent with news updates. Big bomb is eventually going to drop IMO
EEGI thin
Low volume bid whacks might keep it around this level, churning
EEGI slow n steady consolidation / churning all day today. Whacktards need out / people need profits. News would change that obviously.
TXTM .0022 float nearly traded
TXTM 1/2 of float already traded. 112m float. .002
TXTM .002 = next VIIC? 1/3 of float already traded 16minutes into trading day lol
zzzzzzzzzzzzzzzzzzzzzzzzzzzz
EAPH bought more @ .015 News still not on TDA http://www.otcmarkets.com/news/otc-market-headline?id=16374709" rel="nofollow" target="_blank" >http://www.otcmarkets.com/news/otc-market-headline?id=16374709
read my previous post. not on TDA yet. news is also located here: NEWS!
Easton Pharmaceuticals Announces it has Reached a Manufacturing Agreement for the Companys OTC Products; Advances Timetable for Product Launch
Aug 14, 2014 (eTeligis.com via COMTEX) -- TORONTO, ON, Canada, via ETELIGIS INC., 08/14/2014 - - Easton Pharmaceuticals (OTC Pink: EAPH) (PINKSHEETS: EAPH) announces they have sourced out, come to terms and agreed to enter into an agreement with a manufacturing partner for the North American Market and is finalizing a manufacturing Agreement for the Latin American market. Company advances timetable towards its OTC product launches.
Easton Pharmaceuticals has agreed and come to terms with a GMP certified manufacturer located in Toronto, Canada, who will manufacture and supply the U.S. and Canadian markets. Pricing has been determined to be on par with Mexican manufacturers, but the company believes quality control can be better managed in local jurisdictions. Final agreements with the manufacturing company are being drafted who have manufactured and packaged dozens of products for various company's across North America. In addition, Easton has entered into negotiations with other companies for distribution of its OTC products and is close to finalizing an agreement to allow for the marketing and sale of the company's products to commence sometime in the very near term. A formal announcement on the North American manufacturing partner and what we believe to be significant developments involving a distribution partner on our OTC products and other well sought after products within the medical marijuana industry, is anticipated sometime within the next 2 to 3 weeks.
It is expected that the Latin and South American efforts, namely the country of Mexico will still have its manufacturing realized in Mexico. BMV Medica, and Dr. Daniel Bagi, a consultant for Easton Pharmaceuticals have reached an agreement in principle with a manufacturer in Mexico. Initial discussions with another FDA approved manufacturer in Mexico were canceled due to pricing dis-agreements with the company. As previously announced, Easton will be using BMV Medica for its distribution of various products in Mexico and Latin American markets
Carla Pepe, CEO of Easton Pharmaceuticals, commented "Although the launch of Viorra and our other OTC products have recently taken a bit of a back seat to our medical marijuana initiatives, much of the ground work has been laid out where the company now feels it should now move towards manufacturing, marketing and distribution in a diligent and expeditious manner. We anticipate positive announcements will soon be forthcoming that will demonstrate our commitment to our OTC products in conjunction with our medical marijuana initiatives.
About Easton Pharmaceuticals
Easton Pharmaceuticals is a specialty pharmaceutical company involved in various pharmaceutical sectors and others industries such as medical marijuana. The Company owns, designs, develops, and markets topically-delivered drugs and therapeutic / cosmetic healthcare products, focused on cancer and other health issues geared towards male and female sexual dysfunction, wound healing, pain, motion sickness, scar and stretch marks, cellulite, varicose veins and other conditions. The company has ventured into the potentially lucrative medical marijuana industry through an investment into AMFIL Technologies and their groZONE anti-bacterial system and the exclusive option to purchase up to 50% in a medical marijuana grow-op business / facility which has received a letter to build from Health Canada.The company's gel formulation is thought to be an innovative and unique transdermal delivery systemthat can in the future be adaptable in the delivery of Cannabidiol extracts.
For More Information Visit:
http://www.eastonpharmaceuticalsinc.com
Safe Harbor
This news release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (The "Act"). In particular, when used in the preceding of discussion, the words "anticipate," "pleased," "plan," "confident that," "believe," "expect," "possible" or "intent to" and similar conditional expressions are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Any investment made into Easton Pharmaceuticals would be classified as speculative. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company's products and technologies, competitive factors, the ability to successfully complete additional or adequate financing, government approvals or changes to proposed laws and other risks and uncertainties further stated in the company's financial reports and filings.
Contact:
Carla Pepe
Easton Pharmaceuticals Inc.
Tel: +1(416) 619-0291
Tel: +1(347) 284-0192
Email : info@eastonpharmaceuticalsinc.com
SOURCE: Easton Pharmaceuticals , Inc.
Associated Documentation:
http://www.eteligis.com/ViewSubmission.aspx?submissionRequest=27388 - Link to submission on http://www.eteligis.com
http://www.eteligis.com/FileHandler.aspx?submissionRequest=27388&documentRequest=17022 - EAPH_8-14-2014_LST_ETL.docx
Copyright eTeligis Inc. 2014. All rights reserved.
-0-
INDUSTRY KEYWORD: HEALTH
MEDICAL
PHARMACEUTICALS
SUBJECT CODE: COA
HLT
EAPH .0149 news not on TDA or OTC yet: Easton Pharmaceuticals Announces it has Reached a Manufacturing Agreement for the Companys OTC Products; Advances Timetable for Product Launch
Aug 14, 2014 (eTeligis.com via COMTEX) -- TORONTO, ON, Canada, via ETELIGIS INC., 08/14/2014 - - Easton Pharmaceuticals (OTC Pink: EAPH) (PINKSHEETS: EAPH) announces they have sourced out, come to terms and agreed to enter into an agreement with a manufacturing partner for the North American Market and is finalizing a manufacturing Agreement for the Latin American market. Company advances timetable towards its OTC product launches.
Easton Pharmaceuticals has agreed and come to terms with a GMP certified manufacturer located in Toronto, Canada, who will manufacture and supply the U.S. and Canadian markets. Pricing has been determined to be on par with Mexican manufacturers, but the company believes quality control can be better managed in local jurisdictions. Final agreements with the manufacturing company are being drafted who have manufactured and packaged dozens of products for various company's across North America. In addition, Easton has entered into negotiations with other companies for distribution of its OTC products and is close to finalizing an agreement to allow for the marketing and sale of the company's products to commence sometime in the very near term. A formal announcement on the North American manufacturing partner and what we believe to be significant developments involving a distribution partner on our OTC products and other well sought after products within the medical marijuana industry, is anticipated sometime within the next 2 to 3 weeks.
It is expected that the Latin and South American efforts, namely the country of Mexico will still have its manufacturing realized in Mexico. BMV Medica, and Dr. Daniel Bagi, a consultant for Easton Pharmaceuticals have reached an agreement in principle with a manufacturer in Mexico. Initial discussions with another FDA approved manufacturer in Mexico were canceled due to pricing dis-agreements with the company. As previously announced, Easton will be using BMV Medica for its distribution of various products in Mexico and Latin American markets
Carla Pepe, CEO of Easton Pharmaceuticals, commented "Although the launch of Viorra and our other OTC products have recently taken a bit of a back seat to our medical marijuana initiatives, much of the ground work has been laid out where the company now feels it should now move towards manufacturing, marketing and distribution in a diligent and expeditious manner. We anticipate positive announcements will soon be forthcoming that will demonstrate our commitment to our OTC products in conjunction with our medical marijuana initiatives.
About Easton Pharmaceuticals
Easton Pharmaceuticals is a specialty pharmaceutical company involved in various pharmaceutical sectors and others industries such as medical marijuana. The Company owns, designs, develops, and markets topically-delivered drugs and therapeutic / cosmetic healthcare products, focused on cancer and other health issues geared towards male and female sexual dysfunction, wound healing, pain, motion sickness, scar and stretch marks, cellulite, varicose veins and other conditions. The company has ventured into the potentially lucrative medical marijuana industry through an investment into AMFIL Technologies and their groZONE anti-bacterial system and the exclusive option to purchase up to 50% in a medical marijuana grow-op business / facility which has received a letter to build from Health Canada.The company's gel formulation is thought to be an innovative and unique transdermal delivery systemthat can in the future be adaptable in the delivery of Cannabidiol extracts.
For More Information Visit:
http://www.eastonpharmaceuticalsinc.com
Safe Harbor
This news release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (The "Act"). In particular, when used in the preceding of discussion, the words "anticipate," "pleased," "plan," "confident that," "believe," "expect," "possible" or "intent to" and similar conditional expressions are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Any investment made into Easton Pharmaceuticals would be classified as speculative. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company's products and technologies, competitive factors, the ability to successfully complete additional or adequate financing, government approvals or changes to proposed laws and other risks and uncertainties further stated in the company's financial reports and filings.
Contact:
Carla Pepe
Easton Pharmaceuticals Inc.
Tel: +1(416) 619-0291
Tel: +1(347) 284-0192
Email : info@eastonpharmaceuticalsinc.com
SOURCE: Easton Pharmaceuticals , Inc.
Associated Documentation:
http://www.eteligis.com/ViewSubmission.aspx?submissionRequest=27388 - Link to submission on http://www.eteligis.com
http://www.eteligis.com/FileHandler.aspx?submissionRequest=27388&documentRequest=17022 - EAPH_8-14-2014_LST_ETL.docx
Copyright eTeligis Inc. 2014. All rights reserved.
-0-
INDUSTRY KEYWORD: HEALTH
MEDICAL
PHARMACEUTICALS
SUBJECT CODE: COA
HLT
EAPH, in .015 NEWS http://www.otcmarkets.com/news/otc-market-headline?id=16374634
Easton Pharmaceuticals Announces it has Reached a Manufacturing Agreement for the Companys OTC Products; Advances Timetable for Product Launch
Aug 14, 2014 (eTeligis.com via COMTEX) -- TORONTO, ON, Canada, via ETELIGIS INC., 08/14/2014 - - Easton Pharmaceuticals (OTC Pink: EAPH) (PINKSHEETS: EAPH) announces they have sourced out, come to terms and agreed to enter into an agreement with a manufacturing partner for the North American Market and is finalizing a manufacturing Agreement for the Latin American market. Company advances timetable towards its OTC product launches.
Easton Pharmaceuticals has agreed and come to terms with a GMP certified manufacturer located in Toronto, Canada, who will manufacture and supply the U.S. and Canadian markets. Pricing has been determined to be on par with Mexican manufacturers, but the company believes quality control can be better managed in local jurisdictions. Final agreements with the manufacturing company are being drafted who have manufactured and packaged dozens of products for various company's across North America. In addition, Easton has entered into negotiations with other companies for distribution of its OTC products and is close to finalizing an agreement to allow for the marketing and sale of the company's products to commence sometime in the very near term. A formal announcement on the North American manufacturing partner and what we believe to be significant developments involving a distribution partner on our OTC products and other well sought after products within the medical marijuana industry, is anticipated sometime within the next 2 to 3 weeks.
It is expected that the Latin and South American efforts, namely the country of Mexico will still have its manufacturing realized in Mexico. BMV Medica, and Dr. Daniel Bagi, a consultant for Easton Pharmaceuticals have reached an agreement in principle with a manufacturer in Mexico. Initial discussions with another FDA approved manufacturer in Mexico were canceled due to pricing dis-agreements with the company. As previously announced, Easton will be using BMV Medica for its distribution of various products in Mexico and Latin American markets
Carla Pepe, CEO of Easton Pharmaceuticals, commented "Although the launch of Viorra and our other OTC products have recently taken a bit of a back seat to our medical marijuana initiatives, much of the ground work has been laid out where the company now feels it should now move towards manufacturing, marketing and distribution in a diligent and expeditious manner. We anticipate positive announcements will soon be forthcoming that will demonstrate our commitment to our OTC products in conjunction with our medical marijuana initiatives.
About Easton Pharmaceuticals
Easton Pharmaceuticals is a specialty pharmaceutical company involved in various pharmaceutical sectors and others industries such as medical marijuana. The Company owns, designs, develops, and markets topically-delivered drugs and therapeutic / cosmetic healthcare products, focused on cancer and other health issues geared towards male and female sexual dysfunction, wound healing, pain, motion sickness, scar and stretch marks, cellulite, varicose veins and other conditions. The company has ventured into the potentially lucrative medical marijuana industry through an investment into AMFIL Technologies and their groZONE anti-bacterial system and the exclusive option to purchase up to 50% in a medical marijuana grow-op business / facility which has received a letter to build from Health Canada.The company's gel formulation is thought to be an innovative and unique transdermal delivery systemthat can in the future be adaptable in the delivery of Cannabidiol extracts.
For More Information Visit:
http://www.eastonpharmaceuticalsinc.com
Safe Harbor
This news release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (The "Act"). In particular, when used in the preceding of discussion, the words "anticipate," "pleased," "plan," "confident that," "believe," "expect," "possible" or "intent to" and similar conditional expressions are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Any investment made into Easton Pharmaceuticals would be classified as speculative. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company's products and technologies, competitive factors, the ability to successfully complete additional or adequate financing, government approvals or changes to proposed laws and other risks and uncertainties further stated in the company's financial reports and filings.
Contact:
Carla Pepe
Easton Pharmaceuticals Inc.
Tel: +1(416) 619-0291
Tel: +1(347) 284-0192
Email : info@eastonpharmaceuticalsinc.com
SOURCE: Easton Pharmaceuticals , Inc.
Associated Documentation:
http://www.eteligis.com/ViewSubmission.aspx?submissionRequest=27388 - Link to submission on http://www.eteligis.com
http://www.eteligis.com/FileHandler.aspx?submissionRequest=27388&documentRequest=17022 - EAPH_8-14-2014_LST_ETL.docx
Copyright eTeligis Inc. 2014. All rights reserved.
-0-
INDUSTRY KEYWORD: HEALTH
MEDICAL
PHARMACEUTICALS
SUBJECT CODE: COA
HLT
BMIN news: Britannia Fast Tracks Route to Revenues
Aug 13, 2014
OTC Disclosure & News Service
-
Britannia Fast Tracks Route to Revenues
Company Clarifies Imminent Cash Flows From Ready Mined Stockpiles
NEW YORK, NY--(Marketwired - Aug 13, 2014) - Britannia Mining, Inc. (OTC Pink: BMIN) (PINKSHEETS: BMIN) ("Britannia" or the "Company"), a UK based mining development Company, announced today, that Britannia has successfully fast tracked revenues for 2014 -- advancing from exploration operations in Malawi to trading immediate ready mined iron ore stock piles secured by bona fide distribution agreements in Malaysia.
"For clarity, Britannia continues to be very active in Malawi where we are developing roughly 650 sq km of what Bastillion Resources projects stated could be a World Class Asset of well over 1 Billion Tons," stated Kenneth Roberts, CEO of Britannia Mining. "However, it is the yearly distribution of 1.2 million metric tons of ready mined iron ore product, secured by our Malaysian distribution agreements, which has secured revenues for Britannia this 2014. Along with the assistance of our Dubai based South African partners, our first trade of up to 100,000 metric tons of ready mined ore, is set to for purchase and delivery."
On the heels of testing conducted by SGS, the Company advances completion of its initial trade with Swiss buyers. Having the ability to deliver ready mined iron ore from either East or West Malaysia, Britannia should have no shortage of buyers as its port access offers unbound distribution possibilities.
Mr. Roberts concluded, "As we continue to explore Malawi, fast tracking revenues through Malaysian operations has not only provided us with the ability to substantiate shareholder value, but supports our financier's decision to close on its $30 Million SPV."
About Britannia Mining
Britannia Mining is a natural resources development company that is focused on acquiring high quality mineral, mining and other commodity-based projects. The company is committed to developing revenues by conducting exploration, evaluation and trading activities. The company's mission is to secure commodities by developing immediate and near term product pipelines for iron ore and other natural resources.
Acquisition Focus
The Company is targeting revenue producing assets and is currently in negotiations regarding joint venture, acquisitions and trading mineral stockpiles.
Exploration Focus
The company has been developing a high grade iron ore project in Malawi and is currently renewing the Exclusive Prospecting License (EPL) for iron ore over 650 sq. km at Nthale Blantyre. The company is targeting 100 Million Tons (MT) iron at Nthale Hill (20 sq. km).
Britannia Mining has inherited the legacy projects (Gold claims) of the former Micron Enviro Systems in the Yukon and plans to conduct sampling on this area.
For more information, please visit www.BritanniaMining.com.
Safe Harbor
This news release contains forward-looking statements. Forward-looking statements are statements which relate to future events. In some cases, you can identify forward-looking statements by terminology such as "may,'' "should,'' "expects,'' "plans,'' "anticipates,'' "believes,'' "estimates,'' "predicts,'' "potential'' or "continue'' or the negative of these terms or other comparable terminology. These statements are only predictions and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. While these forward-looking statements, and any assumptions upon which they are based, are made in good faith and reflect our current judgment regarding the direction of our business, actual results will almost always vary, sometimes materially, from any estimates, predictions, projections, assumptions or other future performance suggested herein. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results. Readers are referred to the sections entitled "Risk Factors'' in the Company's periodic filings with the United States Securities and Exchange Commission, which can be viewed at http://www.SEC.gov. For all details regarding working interests in all of BMIN's mining prospects or any previous news releases go to OTC Markets website. You should independently investigate and fully understand all risks before making investment decisions.
Contact information
Team BMIN
(646) 580-1153
www.britanniamining.com
Copyright © 2014 Marketwired. All Rights Reserved
BMIN news: Britannia Fast Tracks Route to Revenues
Aug 13, 2014
OTC Disclosure & News Service
-
Britannia Fast Tracks Route to Revenues
Company Clarifies Imminent Cash Flows From Ready Mined Stockpiles
NEW YORK, NY--(Marketwired - Aug 13, 2014) - Britannia Mining, Inc. (OTC Pink: BMIN) (PINKSHEETS: BMIN) ("Britannia" or the "Company"), a UK based mining development Company, announced today, that Britannia has successfully fast tracked revenues for 2014 -- advancing from exploration operations in Malawi to trading immediate ready mined iron ore stock piles secured by bona fide distribution agreements in Malaysia.
"For clarity, Britannia continues to be very active in Malawi where we are developing roughly 650 sq km of what Bastillion Resources projects stated could be a World Class Asset of well over 1 Billion Tons," stated Kenneth Roberts, CEO of Britannia Mining. "However, it is the yearly distribution of 1.2 million metric tons of ready mined iron ore product, secured by our Malaysian distribution agreements, which has secured revenues for Britannia this 2014. Along with the assistance of our Dubai based South African partners, our first trade of up to 100,000 metric tons of ready mined ore, is set to for purchase and delivery."
On the heels of testing conducted by SGS, the Company advances completion of its initial trade with Swiss buyers. Having the ability to deliver ready mined iron ore from either East or West Malaysia, Britannia should have no shortage of buyers as its port access offers unbound distribution possibilities.
Mr. Roberts concluded, "As we continue to explore Malawi, fast tracking revenues through Malaysian operations has not only provided us with the ability to substantiate shareholder value, but supports our financier's decision to close on its $30 Million SPV."
About Britannia Mining
Britannia Mining is a natural resources development company that is focused on acquiring high quality mineral, mining and other commodity-based projects. The company is committed to developing revenues by conducting exploration, evaluation and trading activities. The company's mission is to secure commodities by developing immediate and near term product pipelines for iron ore and other natural resources.
Acquisition Focus
The Company is targeting revenue producing assets and is currently in negotiations regarding joint venture, acquisitions and trading mineral stockpiles.
Exploration Focus
The company has been developing a high grade iron ore project in Malawi and is currently renewing the Exclusive Prospecting License (EPL) for iron ore over 650 sq. km at Nthale Blantyre. The company is targeting 100 Million Tons (MT) iron at Nthale Hill (20 sq. km).
Britannia Mining has inherited the legacy projects (Gold claims) of the former Micron Enviro Systems in the Yukon and plans to conduct sampling on this area.
For more information, please visit www.BritanniaMining.com.
Safe Harbor
This news release contains forward-looking statements. Forward-looking statements are statements which relate to future events. In some cases, you can identify forward-looking statements by terminology such as "may,'' "should,'' "expects,'' "plans,'' "anticipates,'' "believes,'' "estimates,'' "predicts,'' "potential'' or "continue'' or the negative of these terms or other comparable terminology. These statements are only predictions and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. While these forward-looking statements, and any assumptions upon which they are based, are made in good faith and reflect our current judgment regarding the direction of our business, actual results will almost always vary, sometimes materially, from any estimates, predictions, projections, assumptions or other future performance suggested herein. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results. Readers are referred to the sections entitled "Risk Factors'' in the Company's periodic filings with the United States Securities and Exchange Commission, which can be viewed at http://www.SEC.gov. For all details regarding working interests in all of BMIN's mining prospects or any previous news releases go to OTC Markets website. You should independently investigate and fully understand all risks before making investment decisions.
Contact information
Team BMIN
(646) 580-1153
www.britanniamining.com
Copyright © 2014 Marketwired. All Rights Reserved
.0013s about to be on deck. Flippers cashing out what they can. No patience for the news to hit tda and other wires
Subscribe to Ad free and enjoy an ad-free experience
Try Now
Keep the Ads